Jeremy Ahouse, PhD, CSAP
Vice President, Alliances
Merus, a clinical-stage immuno-oncology company developing therapeutics with the goal of treating and curing serious illnesses, uses its proprietary Biclonics® technology to develop novel bispecific antibodies.
Jeremy is responsible for establishing Merus' alliance function and managing a broad research and clinical collaboration with Incyte and other current and future partners (e.g., Simcere, Institut Gustav Roussy). Since 1999 Jeremy has worked in pharmaceutical and biotech research and clinical collaborations with Celgene, Novartis, ImmunoGen, Vantage and Millennium.
Jeremy has served on the board of ASAP and helped to establish the CA-AM and CSAP exams. He contributed to the ASAP best practices guide.
He earned his PhD in immunology and biophysics, and held an HHMI post-doc in developmental genetics. He trained as a mediator and negotiator at Harvard's program on negotiation and has a keen interest in multiparty agreements and in how working together helps research and drug development by improving how we come to know–the epistemology of collaboration.
Soo Bang, MSHA, CA-AM
Vice President, Business Strategy, Integration & Planning
Soo Bang is vice president, business strategy, integration & planning for the Global Pharmaceutical Development & Operations (GPDO). Soo has overall responsibility for the project management, operational excellence, EHS, technical commercialization and GPDO alliance management teams. Previously at Celgene, Soo held the role of executive director, global alliances, where she managed alliance relationships across Hem/Onc, I&I and Early Development, and was the alliance lead for numerous collaborations with clinical programs in both biologics and small molecules. In addition, she helped build the global alliance infrastructure and processes as one of the early members of the team.
Previously, she was the global head of clinical site contracts, where she led a global team responsible for contracts, budgets, central IRBs, and study start-up activities. Previous to Celgene, Soo served as the global investigator lead at Pfizer, responsible for contract and outsourcing across all Pfizer business units, development operations functional service providers, and medical affairs. She also held various leadership positions at NYC Health & Hospitals Corp, director of clinical trials at NYU Medical Center, and Winthrop University Health System. Soo also served as industry lead for the "Advancing the use of Central IRBs" for the Clinical Trials Transformation Initiative, a private public initiative with Duke and the FDA. Soo received her BA and MS from George Washington University and completed her fellowship at Johns Hopkins Health System. Soo is a certified alliance management professional and has a green belt in Lean Six Sigma. She is also actively involved in the career development of others by leading mentorship programs within Celgene and through her strong support and involvement in the Healthcare Businesswomen's Association (HBA).
Emma Barton, PhD
Director, Alliance and Integration Management (AIM)
Emma's key focus within the AstraZeneca alliance and integration management team is divestment transitions, building divestment transition capability and promoting best practise across the enterprise.
Emma joined AstraZeneca in 2000 and has spent over twelve years in business development in various roles where she had experiences of diverse and varied deals including: mergers and acquisitions, spin outs, divestments, late stage licensing, early scientific led alliances and collaborations. With a keen interest in partnering and post-deal management, Emma is currently serving on the ASAP UK Chapter leadership team.
Emma holds a PhD in Organic Chemistry and BSC degrees in Chemistry and Biochemistry from Southampton University.
Director, Alliance Management
Judy is the director of alliance management in the Pfizer worldwide business development group. In her role, Judy is responsible for ensuring alliance effectiveness for Pfizer's oncology clinical research and commercial collaborations. Prior to joining Pfizer, Judy held positions of increasing responsibility at Forest Laboratories and Eisai Inc. in the areas of alliance management, clinical and manufacturing outsourcing, sales operations and finance.
Judy is on the board of trustees for The Valley Hospital in Ridgewood, N.J. She serves on the hospital's investment and audit & compliance committees as well as the research advisory group. Judy holds a BS in business administration & accounting from Meredith College and is a certified public accountant.
Frederic Bonfils, CSAP
VP Corporate Alliance Management
Pierre Fabre Group
Frederic Bonfils has been awarded the Certification Strategic Alliance Professional (CSAP) by the ASAP (Association of Strategic Alliance Professionals). He is member of the Pierre Fabre business development and licensing management committee and is an active member of the French Chapter of ASAP.
Bonfils joined the Pierre Fabre Group in 2005, and prior to taking on his current role in alliance management, he held various positions in marketing, international key account management and marketing/development. During this period, he worked in a wide-range of business units and therapeutic areas, including oral care, OTC, urology, respiratory, and CNS. In all of these activities, the management of external partnerships played a prominent part of his responsibilities.
His previous professional experience over 15 years was gained with Hoechst Marion Roussel and Aventis/Sanofi, working initially as a financial analyst and later in international marketing & sales positions, including international subsidiary management.
Gary Butkus, CA-AM, RPh
Director of Alliance Management
Eli Lilly and Company
Gary Butkus is director of alliance management at Eli Lilly and Company, where he has leveraged 25 years of pharmaceutical experience into being a respected and recognized alliance professional. While at Lilly, he has held numerous roles across the enterprise on both the sales and medical sides of the business and in global shared services, allowing him to become actively engaged in alliance oversight across all phases of drug development. Gary is a published author on alliance-related topics and brings his expertise into his community efforts. He holds various positions including as a trustee at Butler University, a director at the Institute for Study Abroad, and board member for the ASAP Midwest Chapter.
In addition to his CA-AM certification from ASAP, Gary also has completed his certifications in healthcare compliance from Seton Hall University and another from Boston College in corporate citizenship. He is a registered pharmacist with a bachelor's degree from Butler University.
Angela Bylancik, CA-AM
Executive Director, BD&L, Global Alliance Management
Angela Bylancik, CA-AM, CLP joined the pharmaceutical industry in 1984 as a sales representative for Hoffmann-LaRoche. She worked for Roche for 17 years holding positions in market research, in-line marketing, and new product planning. In 2001 Ms. Bylancik joined Novartis as the product director for the respiratory drug Foradil® and took on the role of alliance manager when the product was licensed to Schering-Plough in 2002. From 2002 to 2009, Ms. Bylancik held various roles in new product commercialization and US BD&L including alliance manager and negotiator. In 2009 Ms. Bylancik joined the Novartis Global BD&L group as an executive director of alliance management. Since 2015, Ms. Bylancik has focused on the neuroscience collaboration between Novartis and Amgen. Ms. Bylancik holds a BS in economics from the University of Wisconsin.
Christine A. Carberry, CSAP
Chief Operating Officer
Christine Carberry is a biopharmaceutical leader with the unique ability to transform strategy into results through the power of collaboration. She joined Keryx Biopharmaceutical in the beginning of 2017 as the chief operating officer. In her leadership role she serves on the executive committee while leading initiatives in cross-functional integration, operational excellence, and program management. She heads the manufacturing, technical operations, quality and regulatory functions.
Prior to Keryx, she served as a senior vice president at FORUM Pharmaceuticals. At FORUM, She established the program & alliance management cross-functional matrix to integrate across the entire organization. She also led the CMC, supply chain, and quality functions.
At Biogen for over 25 years, Christine held positions of increasing responsibility as the company advanced from a biotechnology pioneer to an internationally recognized Fortune 500 company.
Christine is a certified strategic alliance professional (CSAP). She holds an MS in innovation and technology management from Boston University, certificates in management and biotechnology strategy from Harvard University, and a BS in biochemistry from the University of New Hampshire.
Elena Cavalli, CSAP
Director, Alliance Management and Corporate Development
Astellas Pharma Europe
Elena Cavalli is an experienced pharma professional with strong alliance management and divestment capabilities. With a highly flexible mind-set, she has held a variety of positions, global, affiliate and regional primarily at Hoffmann La Roche and for the past 11 years at Astellas Pharma Europe. Her increased responsibilities spanned from medical affairs, business development, sales, marketing and corporate development and alliance management. Of note, she has successfully led the transitional period for QUTENZA divestment while in maintaining her role of alliance management lead for strategic alliances.
Since having established the alliance management function within Astellas EMEA, Elena has generated the culture of thorough internal alignment for core partnerships ahead of every key discussion with the partners. This has created an effective professional partnership environment, very well received by upper management and partners. Elena is an enthusiastically active ASAP member; CA-AM and CSAP certified.
Cathy Connelly, MBA, CA-AM
Vice President & Head of Alliance Management
Cathy Connelly, vice president and head of alliance management for Sanofi Genzyme, has over 30 years of biotech/pharma and healthcare-related experience in alliance management, clinical trial and observational research, managed health care, social work and more. Her experience encompasses several therapeutic areas, including: rare diseases, neurology, oncology, cardiac, pulmonology, and infectious disease. Additionally, she has extensive experience in program development, process improvement, business development and in managing complex global teams and alliances.
Cathy is currently responsible for the oversight of Sanofi Genzyme's alliances and alliance management team in the areas of rare diseases, neurology, oncology, immunology, and rare blood disorders, and works in close collaboration with Sanofi Genzyme's executive leadership and the alliance management team to ensure that alliances are run productively and profitably.
Cathy is a published author and a frequently requested speaker at conferences. Most substantially, she was a co-author and/or a reviewer for the three editions of The AHRQ Registries for Evaluating Patient Outcomes: A User's Guide.
Cathy earned her MBA from the MIT Sloan School of Management, BA in Sociology from Framingham State College, and CA-AM certification from the Association of Strategic Alliance Professionals.
Nick Dunscombe, CA-AM
Vice President, Business & Commercial Development
Astellas Pharma Europe Ltd.
Nick is the vice president of commercial development and business development at Astellas for the EMEA Region. This covers all R&D projects developed internally and also projects sourced externally. In addition, Nick and his team manage the alliances and divestments for the EMEA region.
Prior to this role, Nick worked at AstraZeneca for 29 years and held many roles, the last being the head of global integration and divestment management group where he managed many deals with a total value in excess of $15B.
Prior to this role, Nick worked across many business areas including global business development, global R&D (leader for breast cancer portfolio), global marketing (leader for Seroquel, Zomig, Anaesthesia, infection and the early pain portfolio) and regional business management where he was the commercial director for Asia Pacific North and established the JV in China and the Zeneca legal entities in Korea and Taiwan.
Andrew S. Eibling, CSAP
Forty86 Consulting Group
Andy Eibling is 30-year veteran of the pharmaceutical industry and an accomplished alliance management and business development leader with experience in technology, development, commercialization, and supplier relationships.
Andy founded Forty86 Consulting in 2018 in order to continue to elevate the collaborative capabilities of the pharmaceutical industry. He was formerly vice president of enterprise alliance management at Covance, Inc., the drug development division of LabCorp. While at Covance, he created a formal alliance management capability and function. His team was responsible for growth and operational excellence with Covance's most critical client relationships.
Prior to joining Covance, Andy spent over 24 years at Eli Lilly and Company, most recently implementing Lilly's partnering strategy with roles in business development and as a founding member of Lilly's pioneering office of alliance management. During that time Andy managed a variety of partnerships, ranging from early discovery technologies to global drug development alliances with Lilly ICOS, LLC for Cialis® and Amylin for Byetta®.
Andy is a member of the Association of Strategic Alliance Professionals, and a Certified Strategic Alliance Professional (CSAP). He has spoken at numerous conferences and workshops, and his work on "Unique Aspects of Alliance Projects" was published by Wiley in 2010 in the book, Pharmaceutical and Biomedical Project Management in a Changing Global Environment. Andy has a BSME from Purdue University and MBA from Indiana University.
Katherine Ellison, MS, MBA, CA-AM
Associate Director, Alliances
Katherine Ellison leads Illumina's alliances team in its corporate and business development organization. The team is responsible for a wide variety of partnership types, including co-development, co-commercialization, technological innovation, licensing, and supply agreements.
As a dedicated servant leader, Katherine focuses on building and supporting great teams to drive results for Illumina. With more than 15 years' experience working with critical partners, she is responsible for developing Illumina's partnering strategy and assessing organizational fit with potential new partners as part of the company's goal to advance gene sequencing and personalized medicine.
Prior to her work in alliances, she was a product management leader who successfully launched multiple major platforms and products used by thousands of diagnostic testing laboratories worldwide. A lifelong learner, Katherine has bachelor's and master's degrees in chemistry, a graduate certificate in Marketing, an MBA, and earned her certification of achievement-alliance management (CA-AM) from the Association of Strategic Alliance Professionals last year.
Lena Frank, CSAP, PMP
Executive Director of Alliance and Program Management
Lena Frank is the executive director of alliance and program management in Eisai's Oncology Business Group. Before joining Eisai in 2014, Lena held positions of increasing responsibility with Acorda Therapeutics, Alpharma, and Rhone-Poulenc. Her past experience includes business development, project and portfolio management, marketing, product management, and sales. Throughout this work experience she has managed various joint ventures, alliances, and licensing relationships, resulting in more than 15 years of experience with alliances. Over the past 20 years, Lena has also managed a wide variety of projects and programs ranging from drug development to supply chain optimization to the transition of products into and out of various companies. In addition to being a Certified Strategic Alliance Professional, Lena also holds Project Management Professional certification.
Brent Harvey, CA-AM
Director, Alliance Management
Eli Lilly and Company
Brent leads teams focused on maximizing the value of partnered assets at each stage of the development and commercialization cycle.
Brent has played an integral role in some of the largest development and commercial alliances at Lilly, including worldwide partnerships with BMS, Merck KGaA, Daiichi-Sankyo, and Innovent Biologics. He is also the alliance manager on collaborations with venture capitalists, AstraZeneca, GSK, Merck, Sanofi, and WuXi. Brent has responsibilities for M&A integration as well.
Brent has an engineering degree from Purdue and an MBA from Indiana University. He also has a CA-AM and is a certified management accountant (CMA).
Anthony A. Hoerning, CSAP
Strategic Transactions Advisory AG
Anthony Hoerning is the founder of Strategic Transactions Advisory AG, in Basel, Switzerland, and a senior advisor to Vantage Partners, Boston, USA. He is a pharmaceutical industry coach and collaborations bridge-builder with cultural and language versatility. His work with clients encompasses advising both licensors and licensees on all aspects of strategy, negotiation, and alliance management.
As a leading member of Novartis business development and licensing function, he was in charge of the preparation, launch and ongoing implementation, as well as of all renegotiations, of the company's global alliances and created a widely recognized alliance skills training program. He is a trainer and speaker at International Licensing and Alliance Management conferences, and served for many years as a member of the board of the Association of Strategic Alliance Professionals.
Mojgan Hossein-Nia, PhD
Vice President, Head R&D Partnership Office
Mojgan heads the R&D partnership office at Takeda which focuses on defining how Takeda works with partners, optimizes the operational and engagement models, creates mechanisms to integrate partnership inflection points, and value capture elements into the R&D processes, drives "one team" approach, manages large complex enterprise collaborations, and connects the partner network to spark innovation.
A seasoned drug development executive with a record of building and leading business functions across multiple units including strategic partnership development & management, program management, global program leadership, business development & licensing, and global development operations.
Mojgan spent the last 20 years of her career in Novartis Pharmaceuticals, in UK and US. At Novartis, she initiated and implemented strategic outsourcing models with a focus on incorporating innovation into the delivery of clinical development activities. She developed and executed processes for operational excellence. In her role as a global program leader for a partnered cardiovascular program, she worked very closely with the partner to deliver on the strategy in a trusted and transparent way setting an example of how to work with partners at Novartis. In business development & licensing, Mojgan led the search and evaluation of opportunities across multiple indications including cardiovascular, metabolism, and cell & gene therapies in multiple disease areas. Most recently, she worked on the CAR-T program building the program management office and enabling the successful filing and commercialization of the first CAR-T therapy, KYMRIAHTM, in hematological malignancies.
Mojgan joined Takeda in September 2017 as Head of newly created R&D partnership office. In building the Office, Mojgan is looking to embed best practices throughout the partnering lifecycle into existing R&D process and relationship managers, to create the Center of Excellence to continuously improve processes based on learnings, feedback loops & pulse checks, and to build enterprise community to create partner ecosystem and culture.
Kristi Huntington, CA-AM
Director, Pharmaceutical Project Management - Neurodegeneration
Eli Lilly and Company
Kristi currently leads the early phase pharmaceutical program teams within the area of neurodegeneration and immunology. She is responsible for strategic alignment with therapeutic area leadership, cross-functional development plan integration and delivering key milestones on time and within budget to meet business needs.
Throughout Kristi's 18-years at Eli Lilly and Company, she has held various roles within the US, Puerto Rico and Ireland, supporting manufacturing and research and development. Prior to her current role, Kristi was within external innovation, leading due diligence activities for in-licensing, out-licensing and strategic partnering.
Dr. Jeff Karp
Co-founder of six companies
Professor, Brigham and Women's Hospital and Harvard Medical School
Dr. Jeff Karp is a professor of medicine at Brigham and Women's Hospital, Harvard Medical School, Principal Faculty at the Harvard Stem Cell Institute, and an affiliate faculty at the Broad Institute and at the Harvard-MIT Division of Health Sciences and Technology (where he teaches to HST and MIT-Sloan business school students). His work spans the fields of drug delivery, medical devices, stem cell therapeutics, and tissue adhesives. He has published >100 peer-reviewed papers (with >15,000 citations), has given >250 national and international invited lectures, and has >100 issued or pending national/international patents. Several technologies developed in his lab have formed the foundation for multiple products on the market and currently under development and for the launch of six companies that have raised over $100 Million in funding including Skintifique (hightech skincare), Gecko Biomedical (tissue adhesives and 3D printed Biomedical Devices), Alivio Therapeutics (immunomodulation with bioligically responsive materials), Frequency Therapeutics (small molecule regenerative therapeutics), Molecular Infusions (natural products), and Landsdowne Labs (biomedical devices to improve child safety). In 2014, Skintifique brought four consumer healthcare products to market that are sold in pharmacies throughout Europe and are globally available. In 2017, Gecko Biomedical received European regulatory approval (CE mark) for its first tissue sealant product and was recognized by Fierce Medtech as part of their Fierce 15 list of 2017. Frequency Therapeutics began human clinical testing in 2017 for its lead program to treat chronic hearing loss and just completed a successful Phase I safety study in Australia.
Karp's laboratory has been funded by multiple companies, foundations, and governmental funding agencies, including the Bill and Melinda Gates Foundation, NFL, Johnson & Johnson, Phillips, Sanofi, UCB, NIH, DOD, US Army, Kenneth Rainin Foundation, Helmsley Trust, JDRF, Rheumatology Research Foundation, Coulter Foundation, Prostate Cancer Foundation, Brain Science Foundation, American Heart Association, Deshpande Foundation, Institute for Pediatric Innovation, Boston Children's Hospital, Brigham and Women's Hospital, the Government of India and the Government of Korea. Karp also won an internal Shark Tank award judged by Kevin O'Leary (from ABC's Shark Tank).
Karp's work has been published in several high impact journals, including six papers in the Proceedings of the National Academy of Sciences (including two cover features), four in Nature Nanotechnology (including a cover feature), three in Cell Stem Cell, one in Nature Biotechnology, one in Nature Materials, one in Nature Methods, one in Nature Biomedical Engineering, one in Nature Protocols, four in Science Translational Medicine (including two cover features), three in Nature Communications, and two in Blood. Karp also has published a commentary in Nature and another in the New England Journal of Medicine.
Karp's work has been discussed in hundreds of newspapers, online websites, television newscasts, and radio shows around the world, including CNN, ABC News, NBC, Boston Globe, Los Angeles Times, BBC, Discovery, National Geographic, The Atlantic, The Guardian, American Museum for Natural History, Popular Mechanics, and CTV Canada AM, among many others. Karp has also appeared multiple times on CBC's Quirks and Quarks and NPR Science Fridays. Karp has given invited lectures in 16 countries outside of the US including Canada, Israel, Ireland, United Kingdom, Denmark, Aruba, Japan, Korea, Italy, India, Colombia, France, Chile, Switzerland, Saudi Arabia and Germany.
Karp has received over 50 awards and honors. Boston Magazine recently recognized Karp as one of 11 Boston Doctors Making Medical Breakthroughs. The Boston Business Journal recognized him as a Champion in Healthcare Innovation and MIT's Technology Review Magazine (TR35) also recognized Karp as being one of the top innovators in the world (three members from his laboratory have subsequently received this award). Karp is also a Kavli Fellow and was elected to the American Institute for Medical and Biological Engineering's College of Fellows in 2013. His work has been selected by Popular Mechanic's as one of the Top 20 New Biotech Breakthroughs that Will Change Medicine. He gave a TEDMED talk at the Kennedy Center in DC on bioinspired medical innovation, and since 2015 has been a member of the TEDMED Editorial Advisory Board. In 2015 and 2016, he received Breakthrough Awards from the Kenneth Rainin Foundation, and in 2015 was a commencement speaker in at the University of Toronto Faculty of Dentistry and Pharmacy. He also has served as a consultant to the Kenneth Rainin Foundation and the Crohn's and Colitis Foundation on the topic of new technologies for Inflammatory Bowel Disease. He has deep consulting expertise with startups and Fortune 500 companies across a wide spectrum of areas, including drug delivery, medical devices, consumer healthcare products, and stem cell therapeutics.
Karp has had several notable scholarly achievements during his career. In 2010, Karp was asked to serve a two-year term to co-lead the Brigham and Women's Hospital Regenerative Therapeutics Center (making him the youngest faculty at the Brigham and Women's Hospital to direct a research center). He also received the Society for Biomaterials Young Investigator Award and the Coulter Foundation Translational Young Investigator Award. Additionally, he was a visiting professor at Oxford in 2014, presented the Nicholson Memorial Lecture at Composites of Lake Louise in 2015, presented two public lectures at the American Museum of Natural History in 2016, gave a Keynote Lecture at the Ontario Hospital Association's 2017 Health Achieve conference, was a Plenary Speaker at the Tissue Engineering Society Europe conference in 2017, and was a Keynote speaker in 2018 at the combined meeting of the American Society for Peripheral Nerve, American Society for Reconstructive Microsurgery, and the American Association for Hand Surgery.
In addition to his research goals, Karp is dedicated to the career development of next generation bioengineers to work at the forefront of regenerative medicine. Karp was selected as the Outstanding Faculty Undergraduate Mentor among all faculty at MIT and he received the HST McMahon Mentoring award for being the top mentor of Harvard-MIT students. Karp strives to create an educationally conducive environment that fosters the development of scientific confidence. To date, 20 trainees from his laboratory have secured faculty positions (he currently has 4 faculty working in his lab who he promoted from postdoctoral positions) and several have transitioned into impactful careers in pharma, biotech, medtech, and venture capital. Karp dedicates significant time to inspiring the next generation through hosting multiple groups of grade school and high school children to his laboratory each year for lectures and hands on demonstrations (including those from the US, Japan, Sweden, and France), as well as through giving lectures at local and national schools, including schools in Massachusetts, Connecticut, Oregon, and Washington. For example, in 2017 he gave a lecture at the Talcott Mountain Academy in Avon CT (a school for gifted children). He also has been a speaker at the Global Youth Summit at Brandeis University for the past two years. Karp has also collaborated extensively with clinicians, basic scientists, engineers, and fellow bioengineers in the US and in India, where he co-directed an Indo-US Center for Nanobiotechnology, he was invited to help launch a new biomedical engineering program at the Pontifical Catholic University of Chile, and he is currently a principle investigator on a Nanomedicine Center at King Abdulaziz City for Science and Technology (KACST) in Saudi Arabia.
Stuart Kliman, CA-AM
Stuart Kliman is a founding partner of Vantage Partners LLC, and heads up Vantage's alliance practice area. As such, he has worked to help clients build and implement the processes, tools, skills and structures necessary to more effectively manage key alliance relationships. In addition to the alliance space, Mr. Kliman has also worked extensively with organizations looking to engage in more value maximizing and integrated ways with key suppliers and customers.
Mr. Kliman is a regular speaker and writer on issues of alliance and key supplier relationship management.
Kevin Little, CSAP, PhD
Chief Scientific Officer
3D Signatures Inc.
Kevin Little is an accomplished industry executive with a strong history of success in leading life sciences ventures through the creation of collaborative business ecosystems. Kevin is the chief scientific officer of 3D Signatures Inc., overseeing the design, development and implementation of 3DS' research and clinical programs. He is also a consultant with InvenScion, offering strategic advisory services to help facilitate new life sciences collaborations for public and private sector clients. Kevin previously led the PERFORM Centre, a $36 Million health research and community services complex, as the founding chief administrative officer. He also spent several years leading the New Zealand government's economic development efforts to build strategic investment relationships across the biotechnology industry sector, and helped co-found the Asia Collaborative Business Community. Kevin holds a bachelor of science degree in biology from the University of Victoria, a PhD in eperimental, medicine from McGill University, and went on to complete a postdoctoral fellowship in translational neuroscience and clinical gene therapy at the University of Auckland in New Zealand. Kevin is a certified strategic alliance professional.
Executive Director, MRL Strategic Alliances
Merck & Co.
Ellen currently heads strategic alliances at Merck Research Laboratories (MRL) where she and her team manage global research and development alliances.
A long-term Merck employee, Ellen has had the opportunity to advance cross divisionally throughout the organization from finance to European operations to human resources to marketing. Earlier in her career, she embraced an expatriate assignment in Europe, learning the importance of flexing her leadership style to bridge cultural and functional differences. Before joining alliance management, Ellen led an alliance market research team to provide strategic decision support for the Merck/Schering Plough cholesterol partnership in Europe.
Ellen has led the MRL alliance management team since 2012, with the privilege of growing her team to ensure the alliance portfolio is managed in a skilled and professional manner.
Ellen has a passion for seeing the external world through partnering; has been a member of Association of Strategic Alliance Professionals for many years and is currently serving on the program committee for the September 2018 ASAP BioPharma Conference.
Corey McCann, MD, PhD
Founder and Chief Executive Officer
Corey is a physician, scientist, entrepreneur, and healthcare investor.
Previously, he was an investor with MPM Capital and with RiverVest Venture Partners, where he evaluated new investment opportunities, managed relationships with strategic partners, and oversaw board-level strategy and execution at portfolio companies. Prior to MPM, he was with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. He also led McKinsey's Central Nervous System (CNS) expertise group, serving clients across pharma and biotech. He is a founding member of multiple start-ups including Alcyone Lifesciences, a company developing technologies to deliver therapeutics to the brain.
Dr. McCann's post-graduate training was at Harvard University, Washington University in St Louis, and at the Massachusetts General Hospital, and he graduated summa cum laude from The Pennsylvania State University where he was an Evan Pugh Scholar.
Lynda McDermott, CA-AM, MSOD, CSP
EquiPro International, Ltd.
Lynda McDermott is President of EquiPro International, Ltd., an international management consulting firm which specializes in leadership, team and business development for Fortune 500 and medium-size companies and professional services firms. She is also an alliance management consultant for organizations working in strategic partnerships and joint ventures. Her client list includes such companies as Pfizer, Biogen Idec, PricewaterhouseCoopers, BMS, and Sanofi Pharmaceuticals.
Ms. McDermott is co-author of the best-selling book World Class Teams (Wiley). She is a Certified Speaking Professional with the National Speakers Association and is on the faculty of the Association of Strategic Alliance Professionals and received the Certification of Achievement-Alliance Management (CA-AM). Ms. McDermott is an instructor for ASAP's CA-AM certification exam prep workshop and TE-AM Training Workshop, and is an ASAP Educator Provider Partner. Ms. McDermott is a Phi Beta Kappa graduate of Miami University and has a Masters of Science in Organization Development from Bowling Green State University.
Craig McDonald, CA-AM
Director, Alliance Management
Otsuka America Pharmaceutical, Inc.
Craig McDonald is a based in Princeton, New Jersey and is part of the U.S. Business Development and Alliance Management team at. In his role, Craig oversees two key neuroscience and cardio renal alliances and brings together leaders from Otsuka and its collaborators to create a joint vision and drive alliance governance to execute actionable strategies.
Otsuka's collaboration with Proteus Digital Health, Inc., based in Redwood City, California, is focused on developing and commercializing cutting-edge wearable and ingestible technologies to track medication ingestion as well as activity and rest patterns for patients with serious mental illnesses. One achievement of this collaboration is U.S. Food and Drug Administration approval in October 2017 of the first digital medicine system, ABILIFY MYCITE®.
The collaboration between Otsuka and Akebia Therapeutics, Inc., a biopharma company headquartered in Cambridge, Massachusetts, is focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology.
Craig is a demonstrated leader of global pharmaceutical development programs and collaborations. He has over 26 years of experience across multiple therapeutic areas in alliance management, program management and clinical research. Prior to joining Otsuka, Craig held positions of increasing responsibility at Sanofi (formerly: Hoechst), Merck (formerly: Schering) and Novartis and consulted for Celgene Global Project Leadership. Craig earned a Bachelor of Science from the Pennsylvania State University and has achieved the CA-AM Certification.
James C. Mullen
Chairman of the Board of Directors
Editas Medicine, Inc.
James C. Mullen is a biotech leader with more than 30 years of experience building leading biotechnology and pharmaceutical organizations on a global scale. Previously, Mr. Mullen served as chief executive officer of Patheon N.V., a leading global provider of pharmaceutical development and manufacturing services, until its acquisition by Thermo Fisher Scientific, Inc. in August 2017. Before joining Patheon, Mr. Mullen served as chief executive officer and president at Biogen, one of the world's largest biotechnology companies. Prior to being named chief executive officer, Mr. Mullen held various operating positions at Biogen, including chief operating officer, vice president, international, and vice president, operations. Before joining Biogen, he held several manufacturing and engineering positions at SmithKline Beecham.
Mr. Mullen also serves on the Board of Directors of Editas Medicine, Insulet Corporation and Vicarius Pharma AG. He previously served on the Board of Directors of Patheon, Biogen, and PerkinElmer. He was also chairman of the board of directors of the Biotechnology Innovation Organization.
Mr. Mullen holds a bachelor of science in chemical engineering from Rensselaer Polytechnic Institute and a master of business administration from Villanova University.
Chief Business Officer, Companion Diagnostics
Trevor Page is currently the chief business officer of Agilent's companion diagnostic (CDx) division where he leads the business development and alliance management team responsible for establishing and maintaining CDx development partnerships with pharma and biotech. Over the past 10 years, Trevor helped to vitalize and grow Dako's companion diagnostic program into the Agilent CDx division it is today (Dako is now a subsidiary of Agilent). During this tenure, Trevor formed specific business development and alliance management functions as well as innovated partnering models to help successfully navigate the complex, dynamic and evolving nature of CDx collaborations.
Lynnelle Pittet, CA-AM, PhD, MBA
Director, Alliance and Program Management
Wave Life Sciences
Lynnelle leads alliance management at Wave Life Sciences, where she is responsible for growing and developing the alliance management function. She is the alliance manager for Wave's collaborations with Pfizer (hepatic diseases) and Takeda (neurological diseases). Lynnelle is passionate about working with others to develop novel drugs and treatments for patients.
Previously, Lynnelle worked at Cerulean Pharma as director of program and alliance management, Epizyme as senior manager of alliance and program management, and Selecta Biosciences as a senior scientist, where she started doing alliance management. In addition, Lynnelle taught at Simmons College, Harvard University, and Montana State University.
Lynnelle has a PhD in veterinary molecular biology (now microbiology and iImmunology) from Montana State University, a MBA from Simmons College, and a BA in biology (minor in chemistry) from Whitman College. She completed her postdoctoral fellowship at Harvard School of Public Health and Boston University School of Medicine. Lynnelle has been a member of ASAP for several years and completed CA-AM certification in 2017.
Director, Alliance Management
Otsuka America Pharmaceutical, Inc.
Tom Richards is based in Princeton, New Jersey and is the alliance management professional responsible for several Otsuka-Tech Company alliances, including development of siteless trials with Science37, and late stage oncology research and development with Pierre-Fabre, Tzamal, Eisai, and Janssen. In addition to managing alliances, Tom is a member of Otsuka's clinical innovation prioritization team and digital strategy working group.
Tom has over 20 years of diverse experience in the healthcare industry, starting at GlaxoSmithKline where he held progressive roles in sales, regional marketing, market research, and brand management. Later, as vice president, product marketing & development for a small start-up company, Tom led the transformation of print based point-of-care products into innovative digital offerings. He subsequently spearheaded the successful sale of the company in 2013. As vice president, marketing & strategy at Nielsen, Tom championed the development of a dedicated healthcare practice including the successful integration of several targeted company acquisitions.
Tom has a Bachelor of Arts in History from Colorado State University.
Petra Sansom, PhD, CA-AM
Senior Director, Alliance Management
Petra Sansom is a member of the Vertex Pharmaceuticals alliance management team, with responsibility for alliances focused on the discovery and development of transformative medicines to help people with serious diseases like cystic fibrosis.
Prior to her current role, she was Genzyme head of alliance management and a member of the Sanofi alliance management group, with responsibility for alliance management for the Genyzme division collaborations focused on rare genetic diseases. Previously, she was a global alliance director at Hoffmann-La Roche where she was responsible for alliance management of global research, development, and commercial alliances in several therapeutic areas. Petra has over 15 years of experience managing alliances and leading transactional and strategic initiatives. She has great interest in partnering having been a member of ASAP for many years, and has been on the leadership team for the New England ASAP chapter for three years.
She has a JD from Fordham Law School in New York City and a PhD in organic chemistry from the University of Texas at Austin.
Brenda K. Schultz, RN MBA CSAP
President and Principal Advisor
Strategic Partners, LLC
Brenda Schultz is a consultant with over 30 years of experience in the medical device and health care industry. Her experience includes pre-clinical and clinical research, business and market development, strategic partnerships, drug-device combination product development, and regenerative medicine. Brenda's consulting areas include technology scouting, opportunity assessment, due diligence, and strategic partnerships.
Prior to initiating her consultancy in 2017, Brenda was a senior strategic alliance and market development manager at Medtronic Neuromodulation responsible for a portfolio of global initiatives to develop novel targeted drug delivery and neurostimulation therapies. Joining Medtronic in 1990, Brenda managed research and joint development programs with pharmaceutical and biotechnology companies. Brenda completed a 2-year ex-pat assignment in Lausanne, Switzerland for Medtronic Europe collaborating with physicians to conduct cardiac, renal and neurodegenerative disease research.
Prior to joining Medtronic, Brenda worked at teaching hospitals in Minneapolis, Boston, and Tampa specializing in surgical, neuro, and respiratory intensive care. Brenda holds an MBA from the University of Minnesota and a BA in Nursing from St. Catherine University in St. Paul, Minnesota.
Brenda is certified as a strategic alliance professional (CSAP) by the Association of Strategic Alliance Professionals (ASAP) and was awarded patents for medical device design and decision information systems.
Senior Director & Head, Alliance Management
Vin Sharma leads alliance management at Alnylam Pharmaceuticals, building the organization's capability as a world-class leader in partnering, collaborative performance & alliance optimization. Under Vin's purview, his team manages Alnylam's portfolio of partnerships from drug discovery to commercialization, and across rare, cardiometabolic, and hepatic infectious disease. During his tenure, Vin has been a key member of multiple deal teams, kicked-off new partnerships, and has established alliance best practices and processes.
Prior to Alnylam, Vin was most recently at Vertex Pharmaceuticals where he held multiple commercial roles including in global marketing, US marketing, sales, and new product planning. A former consultant, program manager, and case manager Vin leverages his diverse experiences and engagements to strategize, build upon and promote alliance management principles.
Vin holds an MBA from the MIT Sloan School of Management, an MPH with a focus on organizational behavior from Boston University, and a BS in neuroscience & psychology from Brandeis University.
Ben Siddall is a partner at Vantage Partners, LLC, and a member of the firm's sales advisory and alliances practices. Ben works primarily with customer-facing groups to achieve breakthrough results by building deeper relationships with their internal and external stakeholders, identifying new forms of value, and negotiating more effective agreements with customers and between partners. Ben has worked with sales and alliance organizations in numerous industries, with a particular focus on pharmaceutical, medical device, healthcare, and information technology.
Ben regularly works with pharmaceutical companies to enhance their market access effectiveness. This work includes leading negotiation, stakeholder engagement, and collaboration workshops; helping develop customized negotiation support and execution tools; supporting product-specific mock negotiations; and supporting identification and execution of local and global partnerships to support product launches.
During his career at Vantage Partners Ben has contributed to a number of Vantage Partners publications, including the Customer-Supplier Negotiation Study and Extreme Negotiations with Customers. Ben also regularly speaks at conferences on market access negotiation, collaborating with customers, and cross-industry partnerships.
Prior to joining Vantage, Ben led business development and partnership outreach at a start-up technology company in Boston, Massachusetts. He also worked as a lawyer at Covington & Burling in Washington D.C., and as an economic consultant. Ben received his JD from Georgetown University Law Center and his BA in political science from Boston University.
Chief Operating Officer
Samantha Singer is the chief operating officer of the Broad Institute, where she oversees the institute's human resources, finance, facilities, and information technology teams, in addition to the office of strategic alliances and partnering.
Singer joined the Broad after building extensive experience in corporate strategy and organizational effectiveness. She most recently served as vice president for corporate strategy and chief of staff for the chief executive officer at Biogen Idec. Over her six years at the company, she led corporate strategy efforts and oversaw major operations initiatives abroad.
Before her time at Biogen Idec, Singer was a management consultant, first in the health care practice area at the Boston Consulting Group, and then in an independent consulting partnership focused on biotech companies and biomedical research centers.
Singer holds an MS in molecular biology from The Rockefeller University and an MBA from Harvard Business School.
Steven Strongwater, MD
President and CEO
Dr. Steven Strongwater is president and CEO of Atrius Health, a non-profit accountable care organization with 6,800 employees serving 720,000 patients across eastern Massachusetts and a national leader in delivering high-quality coordinated medical, home health and hospice care.
Dr. Strongwater previously served as Geisinger Health System's chief transformation officer and chief medical executive for acquisition integration. While at Geisinger, he provided transformational leadership developing new models of care, as well as strategies and tactics to improve value, leveraging analytics and simulation tools.
Dr. Strongwater has served also in a variety of leadership positions including assistant chancellor, associate dean for clinical affairs, chief of staff and chief executive officer, at UMass Medical Center, the University of Connecticut Health Center and Stony Brook University Medical Center, respectively. Currently, he serves on the Mass Digital Health Council, IBM Watson Advisory Board, Janssen Healthcare Innovators Council, Healthcare Executives Network, and on the Zetema Project. He has a long standing interest in population health, physician resilience, quality, and patient safety.
Dr. Strongwater completed his undergraduate medical education at Upstate Medical Center and a research fellowship in rheumatology at the University of Michigan. He is a member of AOA and Phi Beta Kappa honor societies.
David S. Thompson, CA-AM
Chief Alliance Officer
Eli Lilly and Company
David is an internationally recognized alliance architect and alliance builder, specializing in making alliances productive and profitable with a track record of: designing and operating effective and efficient alliances; successfully managing and negotiating alliance conflict; and developing high performing alliance management teams. David has published over 20 articles on the topic of alliance management and has been sought out by Fortune 100 companies outside of the pharma industry to consult on their alliance management programs. David regularly teaches alliance management courses as a guest lecturer at universities and has taught scores of alliance managers not only from pharmaceutical and biotech companies, but also high tech, insurance, petroleum, funeral, automobile, and financial services industries. David also serves as a board member of the Association of Strategic Alliance Professionals.
Currently, David is the chief alliance officer at Eli Lilly and Company (Lilly). As the leader of Lilly's alliance management group, David is responsible for establishing and maintaining all major development, commercial, and manufacturing partnerships. He also oversees the integration of companies brought into Lilly via mergers and acquisitions. David has played a key role in many major alliances and acquisitions at Lilly, working with Boehringer Ingelheim, Amylin, Daiichi Sankyo and IMCLONE. His involvement begins during the due diligence process and continues throughout each alliance's lifecycle.
Prior to his role as chief alliance officer, David held leadership positions in sales, marketing, market research, pricing, new product planning, business development, and corporate strategy.
Steve Twait, CSAP
Vice President, Alliance and Integration Management (AIM)
Steve has responsibility for AstraZeneca's alliance and integration management (AIM) strategy and execution capabilities. Steve's team leads the integration of all major acquisitions, the transitions for divestments, and management of key alliances for AZ. Steve joined AZ in January 2015, after spending 26 years at Eli Lilly and Company where he was a founding member of Lilly's office of alliance management. Steve is a well published author in Pharmaceutical Executive, PLG's Business Development & Licensing Journal, and Strategic Alliance Magazine and is a board member and treasurer of the Association of Strategic Alliance Professionals.
Jan Twombly, CSAP
The Rhythm of Business, Inc.
For nearly 20 years Twombly has served as a trusted, expert advisor to global and emerging companies. She works as an extension of the partnering and alliance management team, helping them develop their ability to accelerate outcomes from partnering and alliances. Partnering with the executive suite, she helps companies reach higher levels of alliance success by integrating partnering into all aspects of the business.
A few of the many companies she has worked with include Abbott, Astellas, AT&T, Bayer, Becton Dickinson, Biogen, Boehringer Ingelheim, Colgate-Palmolive, Dun & Bradstreet, EMC, Equifax, FIS, IBM, Intel, Novartis, Sanofi, Shire, and Xerox.
Twombly serves on the executive and management committee of the Association of Strategic Alliance Professionals (ASAP). She is editorial advisor to ASAP Media, which publishes Strategic Alliance Magazine, and contributed to The ASAP Handbook of Alliance Management. Together with business partner Jeffrey Shuman, Twombly has a rich history of developing, publishing, and presenting strategic and practical thinking that advances the art and science of partnering and alliance management.
Jason M. Urban, PhD
Senior Director, Business Strategy & Process Excellence, Global Pharmaceutical Development & Operations
Jason built and leads Celgene's business strategy & process excellence function in the Global Pharmaceutical Development & Operations organization (GPDO). Celgene's GPDO is responsible for biopharmaceutical development, manufacturing and supply of innovative therapies for unmet medical needs in cancer and immune-inflammatory disease.
Jason's function is focused on progressing the organization from functionally oriented to cross-functional, end-to-end oriented operations. This is being accomplished through core capabilities and responsibilities for business development/global alliances alignment within GPDO and regulatory CMC, business strategy, long range planning, business case development, business process management (OpEx), as well as, internal & external communications.
Prior to his current role, Jason built and led Celgene's global quality risk management and surveillance department under quality operations, responsible for quality metrics, health authority communications & risk management. Prior to Celgene, Jason held risk management and compliance positions in the office of strategic programs and the office of compliance in the FDA's Center for Drug Evaluation and Research. During that time, he led activities in the areas of compliance, quality, supply chain, regulatory CMC, and policy development.
Jason holds a PhD in Cellular Biology with a focus on cancer signaling. He also completed several postdoctoral residencies in molecular neuroscience and cell therapies. Jason is also a member of the editorial board of Life Science Leader Magazine.
Chief Commercial Officer
Alex Waldron is a senior level global bio/pharmaceutical business leader with 27+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations. He currently serves as chief commercial officer at Pear Therapeutics.
He has a proven record of building and leading business strategy and operations. In his career, Alex has driven enterprise value from portfolio strategy through to commercial launch. In previous roles, Alex has architected the structure and growth of several divisions at Biogen and helped to shape the emerging biosimilar market at Epirus Biopharmaceuticals.
Alex has also worked in numerous commercial and operations roles at Genzyme, Astra Zeneca, Pfizer and Bristol-Myers Squibb.
VP Business Development, Neuroscience
Johnson & Johnson Innovation / Janssen Business Development
Lucinda (Cindy) heads the neuroscience business development team which includes scientific finding, licensing transactions, mergers, acquisition, out licensing, divestitures and alliance management.
With over 24 years of broad industry experience, Lucinda began her pharma career in Canada. In 1999, she joined the Johnson & Johnson family of companies and has held various USA and global roles of increasing responsibilities, including sales, marketing, new product development, alliance management, and business development leadership. Lucinda has been responsibility for the leadership and oversight of some of Janssen's longest and largest global commercial alliances in addition to leading the global integration of Johnson & Johnson's single largest asset REMICADE®, back into the organization in 2011.
Just prior to joining the Janssen business development leadership team, Lucinda led the immunology business unit in Australia, returning to the USA in 2014 as VP alliance management, Janssen, responsible for leading the total pharmaceutical portfolio of collaborations.
Lucinda received her Bachelor of Science degree from the University of Alberta, Canada.
Stacie Wild, PhD
Business Development Director, Alliance Management
Stacie is a director in Amgen's alliance management group currently supporting the Amgen and Novartis neuroscience collaboration. She previously supported other multi-product collaborations and several out-licensed products in the inflammation portfolio.
An 18-year veteran of Amgen, Stacie has held various roles in the research and development organization developing products across many therapeutic areas, several of which included partnerships with other pharmaceutical companies. In 2013, she transitioned to alliance management to support collaborations full-time. Prior to Amgen, Stacie worked in product safety assurance at Colgate-Palmolive.
Stacie has a Bachelor of Science degree in biochemistry from Eastern Michigan University and a PhD in pharmacology and toxicology from the University of Arizona.